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Aim. To examineinteraction between historyof cancerin ﬁrst-degree relatives andtobacco smokingin index patients ofpancreatic
adenocarcinoma.Methods.We carried out a case-control involving113 patients withpancreatic adenocarcinomaand 110 controls
over a 12-month period at the Freeman Hospital, Newcastle upon Tyne, UK. They were all administered a detailed tobacco
exposure questionnaire and a family history questionnaire. We calculated cumulative tobacco exposure and risk for pancreas
cancer. Results. Both smokers (OR 3.01 (95% CI 1.73 to 5.24)) and those with a family history of malignancy (OR 1.98 (95%
CI 1.15–3.38)) were more likely to develop pancreatic cancer. Having more than one ﬁrst-degree relative with cancer did not
signiﬁcantly further increase the risk of pancreatic cancer. Amongst pancreatic cancer cases, cumulative tobacco exposure was
signiﬁcantly decreased (P = .032) in the group of smokers (current and ex-smokers) who had a family history of malignancy
[mean(SD):30.00(24.77)pack-years versus 44.69(28.47)pack-years with no such history].Conclusions.Individuals with a family
history of malignancy are at an increased risk of pancreatic cancer. Furthermore, individuals with a family history of malignancy
and who smoke appear to require a lesser degree of tobacco exposure for the development of pancreatic cancer.
1.Introduction
The major risk factors for pancreatic cancer are increasing
age, tobacco smoking (2004; [1]), and family history of the
cancer [2]. The strongest avoidable risk factor in sporadic
pancreatic cancer development is tobacco smoking. Familial
pancreatic cancer occurs at an earlier age, [3] is clustered in
families[4,5]andhasthesamepoorprognosisasitssporadic
counterpart. There are other inherited conditions in which
pancreatic cancer occurs as part of a syndrome [6], with 5–
10% of pancreatic cancer cases being associated with heredi-
tary syndromes [7],of which familial pancreatic cancer is the
mostcommon.About30%ofsporadicpancreaticcancersare
causally related to smoking. The remainder have been poorly
characterised in termsofaetiology.Althoughafamily history
of cancer is known to increase the risk of pancreatic cancer,
theadditionaleﬀectofsmokinginthesepatientsisunknown.
Analysis of genetic risk of cancer has shown that
most nonhereditary, sporadic cancers develop in genetically
predisposed individuals. This predisposition is most likely a
result of several low penetrant genes rather than single-gene
mutations [8, 9]. These low penetrant genes which by them-
selves have small relative risks, by virtue of being common in
the population may have large population, attributable risks
[10]. It has been observed from epidemiological studies that
the ﬁrst-degree relatives of sporadic cancer patients have a
2-3-fold higher risk of developingcancer at the same site and
this has also been described for pancreatic cancer but in only
retrospective studies [10–12]. Familial clustering observedin
certain sporadic cancers without obvious Mendelian inheri-
tance suggests that there is a genetic component in addition
to environmental factors [13]. This could be explained on
the basis that family members with the similar genetic
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this leads to the phenotypicmanifestation of the disease. The
interplay of environmental and genetic factors appears to
play a critical role in the development of pancreatic cancer
and this has been well described for its familial form [14].
Onthisbackground,itis reasonable tosuppose thatsporadic
adenocarcinoma of pancreas, which forms the majority,
is due to gene-environment interaction (GEI). These have
been poorly characterised and therefore the majority of
sporadic pancreatic cancers have been considered to have
no identiﬁable cause and therefore no high-risk groups are
identiﬁable.
Investigation of this gene-environment interaction pro-
vides us with an opportunity to not only understand the
disease better but also to stratify risks and develop strategies
to improve outcome. This interindividual genetic variation
modulates risk for malignancy [15] and identiﬁcation of
these genetic diﬀerences forms the basis of risk stratiﬁcation
thereby enabling targeted prevention or earlier diagnosis
[16, 17]. This is especially pertinent to pancreatic cancer,
as it has a particularly poor prognosis and palliation of
symptoms is the most common therapy patients receive—
mainly because of late diagnosis although there are other
biological factors that play a role. Towards this end we have
sought to investigate the relationship between these factors
(tobacco smoking and a family history of malignancy) by
comparing groups of patients with exposure to a known
environmental risk factor for pancreatic cancer but with
diﬀerent genetic backgrounds.
2.Methods
Patients with pancreatic adenocarcinoma were prospectively
identiﬁed, as part of an ongoing molecular epidemiological
study. They were invited to take part in this research project
which was approved by the Local Research Ethics Commit-
tee, and the clinical governance guarantor was the Newcastle
upon Tyne Hospitals Foundation NHS Trust, Newcastle
upon Tyne, UK. Over a period of twelve calendar months
between June 2005 and May 2006, consenting individuals
were administered a questionnaire which recorded, in a
face-to-face interview, life-style factors including tobacco
smoking habit, alcohol consumption, and occupation. A
detailed family history relating to malignant disease in
their ﬁrst-degree relatives was also obtained directly from
the patient. The World Health Organization Monitoring
of Cardiovascular risks (MONICA) questionnaire was used
to record detailed tobacco exposure. This enabled us to
calculate cumulative tobacco exposure in individuals and
to arrive at total pack-years of exposure (total pack years
of smoking = (number of cigarettes smoked per day ×
number of years smoked)/20(1 pack has 20 cigarettes)).
We also collected data on the mode of diagnosis of the
adenocarcinoma of pancreas.
First-degree relatives (FDR) were deﬁned as biological
parents, siblings, and oﬀspring. Individuals were considered
smokers (current and ex) if they had smoked at least 100
cigarettes in their life-time and nonsmokers if they had not
smoked this amount. They were considered ex-smokers if
they had stopped smoking for a period of one year. Cases
and controls were divided into 2 groups on the basis of
a positive family history in ﬁrst-degree relatives (FDR):
FDR+, in whom there was history of malignancy (other than
dermatological and primary brain malignancies) in ﬁrst-
degree relatives; and FDR−, in whom there was no such
history. FDR1 denoted index cases with a single FDR with
malignancy;FDR>1denotedthosewithmorethanoneFDR
with malignancy.
We report here the interactionbetween tobaccoexposure
and a family history of malignancy in this group of patient.
Continuous variables were compared by the student t-
test and ANOVA for parametric variables and the Mann-
Whitney U test for nonparametric variables. Correlation
was tested using the Pearson’s chi-square test. Directional
measures were employed as necessary. Odds ratios with
95% conﬁdence interval were calculated to quantify relative
risk. SPSS version 15.0 (SPSS, Inc., Chicago IL, USA) was
the software platform used for computing these tests. All
continuous data are reported as mean (SD).
3.Results
3.1. Study Population. A total of 145 patientswere diagnosed
with pancreatic cancerin the study period, one of whom was
excluded because of a diagnosis of Li-Fraumeni syndrome
which is known to predispose to pancreatic cancer. Three
further patients declined to enter the study leaving a total
of 141 patients who agreed to take part. The mode of
diagnosis of pancreatic malignancy was cytological and/or
histological evidence of pancreatic ductal adenocarcinoma
in 102 patients (72%) and a combination of radiological,
biochemical (serially rising CA19-9), and clinical ﬁndings in
39 (28%) patients.
The controls numbering 122 were composed of patients
who attended the Freeman Hospital, Newcastle upon Tyne,
UK for elective hernia repair surgery (n = 13), chole-
cystectomy (n = 25), endoscopic treatment of bile duct
stones, and/or benign biliary strictures (n = 9) and
patients attending the anticoagulation clinic (indications
included cardiac arrhythmia, prosthetic cardiac valves in-
situ, following pulmonary embolism and other nonneoplas-
tic conditions) (n = 75). All patients with benign biliary
strictures were followed up for a median of 38 months
(range 30–54) and are all currently well with no diagnosis
of malignancy. Aetiology of these strictures was previous
surgery in the vicinity (cholecystectomy, gastrectomy for
benign disease) and previous biliary pancreatitis.
3.2. Cases and Controls. Of the 141 cancer patients, 113 with
reliable family history were included into this study (family
history data being unavailable in 21 and incomplete in 7).
Of these 113 pancreatic cancer patients, 60 had a family
history of a malignancy in ﬁrst-degree relatives (caFDR+)
whilst 53 were caFDR−. The mean (SD) age at diagnosis for
pancreatic cancer cases was 65.1 (10.67) years. There was no
diﬀerence (P = .35) in the mean (SD) age between caFDR+
and caFDR− groups (65.93 (8.90) and 62.23 (13.65) years,
resp.). The overall gender ratio was 66:47 (m:f), (34:26 for
caFDR+ and 32:21 for caFDR−).Journal of Oncology 3
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Figure 1: Tobacco smoking behaviour in cases and controls.
The controls numbered 122, of which 110 were included
due to constraints of reliability or completeness of family
history: controls with a positive family history ofmalignancy
(coFDR+) = 40, controls with a negative family history of
malignancy (coFDR−)=70,controlswith unavailablefamily
history of malignancy = 5, and controls with incomplete
family history of malignancy = 7. Mean (SD) age of controls
was 60.07 (14.34) years. There was no signiﬁcant diﬀerence
between the ages of coFDR+ and coFDR− groups. The
overall gender ratio was 56:54 (m:f) (22:18 for coFDR+
and 34:36 for coFDR−).
Table 1 summarises the demographics, smoking behav-
iour, and cumulative tobacco consumption, (overall con-
sumption and stratiﬁed by FDR status) of our study
population (total 223; cases 113 and controls 110).
3.3. Tobacco Exposure and Risk of Pancreatic Cancer. There
were 80 pancreatic cancer patients who had experienced
signiﬁcant tobacco exposure at some point in their lives;
33 were current smokers and 47 were ex-smokers who had
stopped smoking at a mean (SD) of 19.19 (14.48) years
prior to diagnosis of adenocarcinoma of pancreas. The mean
(SD) cumulative tobacco exposure in these 80 individuals
was 36.98 (27.43) pack-years. There were 33 nonsmokers.
The mean (SD) cumulative tobacco exposure in all controls
who had experienced tobacco exposure (n = 51, current
smokers = 29 and exsmokers = 22) was 37 (13.20) pack-
years and this was signiﬁcantly lower (P = .029) than that in
pancreatic cancer cases. There were 59 nonsmokers amongst
the control population. There was no signiﬁcant diﬀerence
in the number of current smokers between the cases and
controls but signiﬁcant diﬀerences were seen in the numbers
of past smokers (Table 1 and Figure 1).
The relative risk for an ever smoker (current and ex)
for the development of pancreatic cancer is nearly 3 times
that of a non-smoker (OR 3.01 (95% CI: 1.73 to 5.24)).
There was no signiﬁcant diﬀerence in the mean age between
the cases and controls; however, there was a deﬁnite early
onset of adenocarcinoma of pancreas in current smokers. A
consistent early occurrence of adenocarcinoma of pancreas
by about 6-7 years was seen amongst current smokers as
compared to nonsmokers, which is independent of family
history of cancer (Table 2). FDR status did not aﬀect the age
of onset of pancreatic cancer in our cohort (datanot shown).
3.4. Family History of Cancer in FDRs Inﬂuencing Risk for
Pancreatic Cancer. A history of malignancy in FDR was
present in 60 (m:f = 34:26) and absent in 53 (m:f =
32:21) cases. Amongst controls, the coFDR+ numbered
40 and coFDR− was 70. The relative risk of development
of adenocarcinoma of pancreas for cases with a positive
h i s t o r yo fm a l i g n a n c yi nF D R( c a F D R + )w a sn e a r l yt w i c e
that of cases with a negative history of malignancy in FDR
(caFDR−) individuals (OR 1.98 (95% CI: 1.15–3.38)). This
was independent of any further risk conferred by smoking.
Of the 60 cases caFDR+, 36 had a single relative with cancer,
1 7h a d2r e l a t i v e s ,6h a d3 ,a n do n eh a d4r e l a t i v e sw i t h
cancer. In total, there were 92 malignancies in caFDR+ and
58inthecoFDR+.Thediﬀerentmalignanciesinthesegroups
are depicted in Figure 2.
3.5. Interaction between Tobacco Smoking and Family History
of Cancer in FDRs in Inﬂuencing Risk for Pancreatic Cancer.
Most importantly amongst cases, there was a signiﬁcantly
decreasedcumulativetobaccoexposureinthecaFDR+group
(P = .016) as compared to the caFDR− group. The
mean (SD) cumulative pack-years of smoking was 30.00
(24.77) in the caFDR+ versus 44.69 (28.77) in the caFDR−
group. Mean (SD) cumulative tobacco exposure in coFDR+
was 22.45 (13.18) and that in coFDR− was 17.33 (14.11).
This was not statistically diﬀerent (P = .171). There was,
however, a signiﬁcantly greater tobacco exposure amongst
caFDR+ than their coFDR+ case counterparts (P = .00)
(Table 1). The relative risk for adenocarcinoma of pancreas
was higher in smokers in both FDR+ (OR 2.85 (95% CI:
1.24 to 6.65)) and FDR− (OR 3.18 (95% CI: 1.48 to 6.82))
groups, but the amount of tobacco exposure lower in the
caFDR+.
Next we divided the cases with a family history of cancer
in their FDR into 2 groups—caFDR 1 (n = 36): one FDR
with cancer and caFDR > 1( n = 24): cases with more than
1 FDR with cancer. We did not ﬁnd a signiﬁcant diﬀerence
in the mean (SD) cumulative pack years of tobacco smoking
in between these groups (FDR1: 33.70 (29.24), FDR2: 25.07
(16.68); P = .269).
4.Discussion
Following signiﬁcant advances in imaging to aid in patient
selection for deﬁnitive treatment and improvement in surgi-
cal techniqueand perioperativecare, prognosis forresectable
pancreatic cancer has improved appreciably. Chemotherapy
hasasigniﬁcantroletoplayinselectedcases[18].However,it
doesappearthatfurthersigniﬁcant improvementinoutcome
from the illness will be directly related to the ability to detect
thedisease early and institutepromptmanagement. This will
require identiﬁcation of high-risk groups in whom targeted
screening can be employed and early or precursor lesions
recognized [19] and this has been demonstrated successfully
in familial forms of thedisease [20] and has been found to be
cost-eﬀective [21].4 Journal of Oncology
Table 1: Summary of results.
Pancreatic cancer cases Controls P value
Total 141 122
Number included into analysis 113 110
Male 66 (58%) 56 (51%) ns
Female 47 (42%) 54 (49%) ns
Mean age 65.1 (10.67) 60.07 (14.34) ns (t-test)
Ever smokers 80 51 P = .023
Non smokers 33 59
FDR+ 60 40 P = .010 (chi-squared)
FDR− 53 70
FDR+ Mean (SD) cumulative
tobacco exposure in pack years
30.00 (24.77)∗ 22.45 (13.18)∗∗ .229 (Mann-Whitney)
FDR− Mean (SD) cumulative
tobacco exposure in pack years
44.69 (28.47)∗ 17.33 (14.11)∗∗ .003 (Mann-Whitney)
Mean (SD) overall cumulative
tobacco exposure in pack years
36.98 (27.43) 21.19 (22.04) .008 (Mann-Whitney)
∗P = .016 (Mann-Whitney) ∗∗P = .171 (Mann-Whitney)
∗Compares cumulative tobacco exposure between FDR+ and FDR− amongst pancreas cancer cases.
∗∗Compares cumulative tobacco exposure between FDR+ and FDR− amongst controls.
Table 2: Age of onset of all cases of adenocarcinoma of pancreas (n = 113) by smokingstatus (Mean (SD) years).
Pancreas cancer patients
grouped based on family
history of malignancy status
Smokingstatus
Current smoker Current and
Ex-smoker Ex-smoker Non-smoker Ex and
non-smoker ANOVA P
Combined caFDR+ and
caFDR− (n = 113)
60.12 (8.18) 67.59 (10.10) 66.36 (12.17)
60.12 (8.18) 66.36 (12.17) #.005
64.51 (10.01) 66.36 (12.17) ∗.40
60.12 (8.18) 67.08 (10.95) +.001
#Compares age of onset of pancreatic cancer between current and non-smokers
∗Compares age of onset of pancreatic cancer between non-smokers and combined group of current and ex-smokers
+Compares age of onset of pancreatic cancer between current smokers and combined group of ex- and non-smokers.
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Figure 2: Types ofmalignanciesin caFDR+ (n = 60) & coFDR+ (n = 40).Totalnumber ofmalignanciesincaFDR+ =92 (in60individuals)
and in coFDR+ = 58 (in 40 individuals).Journal of Oncology 5
In our prospective hospital-based case-control study, we
have seen that pancreatic cancer patients smoked more than
our control group and an ever-smoker individual had a 3-
times higher risk for the development of pancreatic cancer
than a non-smoker. These are well-recognised ﬁndings.
In addition, however, there were other signiﬁcant results;
smokers on average developed the cancer about 6-7 years
earlier than nonsmokers which was independent of a family
history of malignancy and has been previously described on
the basis of WHO cancer mortality data and SEER cancer
incidence data [22]. More importantly a family history of
malignancy in ﬁrst-degree relatives appeared to decrease
the amount of tobacco exposure (as measured by pack-
years)requiredforthedevelopmentofpancreaticcancer.The
earlier onset of the disease was however not related to FDR
status.
It is accepted that familial pancreatic cancer appears
to develop at an earlier age as compared to its sporadic
counterpart, and tobacco exposure is the most important
factor inﬂuencing the penetrance of the FPC gene [14].
Smokers in FPC [23, 24] and in hereditary pancreatic cancer
syndromes, speciﬁcally hereditary pancreatitis patients [25],
developthe disease about 10 years earlier, demonstrating the
interaction between an inherited susceptibility to cancer and
an environmental carcinogen. A recent report has described
gene-environment interaction in a study of cases only,
although the sample size was large [26]. We have now shown
for the ﬁrst time that smokers who also have a family history
of cancer develop the disease at a lower level of exposure.
In smokers, the disease also appears to develop earlier.
This might be due to continued or faster accumulation of
genotoxic mutations secondary to a variety of factors, one
of which might be an ineﬃcient DNA repair mechanism.
Other genetic and environmental factors might play a role
and this will need further elucidating. For example, a recent
report has shown an earlier age of onset of pancreatic cancer
in those who had a high BMI during their teen and younger
years [27].
The groups of index cases and controls with and without
a family history of cancer were comparable given their
similar age distribution and gender distribution. We have
obtained history of cancer in FDR from index cases and
controls and itis known thatsuch information is reliable and
accurate especially with regard to FDRs [28]. The reliability
of information obtained, however, decreases with regard to
other relatives [29, 30], and we have therefore restricted our
study to data on ﬁrst-degree relatives. It has been suggested
that, if anything there is under reporting of family history of
cancer especially with regard to individuals with colorectal
neoplasms [31]. Other details of the illness in the FDR such
as age of onset (of the cancer in the relative) are unreliable
especially in older probands and we have therefore not
utilised such data in our study [29]. We have not performed
genetic analysis in this group of patients to conﬁrm that they
are not familial cancers as most familial pancreatic cancers
are not due to known mutations. It is likely that our patients
represent sporadic malignancies due to the fact that the age
distribution of the group of patients is normal and there was
no diﬀerence in the mean (SD) of the age at diagnosis of
theindexcasesintheFDR+andFDR−groups(65.93(10.67)
and 64.57 (12.38) years).
We have also demonstrated in this prospective group
of patients, that those with a family history of cancer as
evidenced by the occurrence of a malignancy in an FDR are
not only at twice the risk of developing pancreatic cancer
(OR1.98(95%CI:1.15–3.38))butmoreimportantly require
less of a genotoxic exposure as compared to those who do
not have such a genetic vulnerability (Table 1). Just under
2/3rds of FDR+ index cases (n = 36; 59%) had just a single
ﬁrst-degree relative with malignancy. In the FDR+ group,
there was a decreased tobacco exposure required for the
development of adenocarcinoma of pancreas but this did
not depend upon the number of relatives with malignancy,
as the FDR > 1 group did not demonstrate a signiﬁcantly
decreased cumulative tobacco exposure. It is well accepted
that a family history of cancer is a risk factor for most cancer
types. With respect to adenocarcinoma of the pancreas, a
recent meta-analysis of seven case-control and two cohort
studies involving 6,568 pancreatic adenocarcinoma cases
concluded that a family history of adenocarcinoma of the
pancreas conferred double the risk (1.80 (95% CI: 1.48–
2.12)) for the disease in individuals with such a history
compared to those without [32]. A recent cohort study
from the PanScan consortium [33] and prospective followup
of participants of Cancer Prevention Study-II [34]h a v e
suggested an association between family history of various
cancers especially prostate cancer and pancreatic cancer. An
important additional ﬁnding from our study is conﬁrmation
that the presence of any malignancy in FDR, apart from
dermatological and primary brain malignancies, appears to
confer an increased risk for pancreatic adenocarcinoma. We
have not performed speciﬁc FDR malignancy associated risk
analyses in view of the small size of our study population.
This is, however, intended for the future when a suﬃciently
large number of cases have been accrued.
In the presence of a family history of malignancy (i.e.,
increased susceptibility), a decreased dose of an environ-
mental carcinogen is suﬃcient to cause cancer (cumulative
tobacco exposure in FDR+ (30 (24.77) versus FDR− (44.69
(28.47) (P = .00)). It is possible that the decreased
tobacco dose demonstrated in the caFDR+ group is due to
a genetic or other environmental factor which potentiates
the genotoxic eﬀect of tobacco-derived carcinogen by either
impairing the processing of tobacco-derived carcinogen into
inactive metabolites or causing the ineﬃcient or incomplete
repair of genetic damage induced by it. Genetic factors such
as poor DNA repair, impaired carcinogen metabolism and
environmental factors may interact in the development of
tobacco-related cancers, including that of the lung, bladder
a n dh e a da n dn e c k[ 35–38] .T h e r ei ss o m ee v i d e n c ef o rt h i s
in pancreatic carcinogenesis too from molecular epidemio-
logical studies: the presence of XRCC2 Arg188His polymor-
phismmodulatesriskforpancreaticcanceramongstsmokers
[39]; XPD gene polymorphisms—exon 10 Asp(312)Asn and
exon 23 Lys(751)Gln polymorphisms—inﬂuence risk for
smoking associated adenocarcinoma of the pancreas [40];
XRCC1 399Gln allele determines susceptibility to smoking
induced pancreatic cancer [41]; deletion polymorphism in6 Journal of Oncology
GSTT1 is associated with an increased risk of adenocarci-
noma of the pancreas amongst Caucasians [42]. None of
these studies, however, has ascertained the risk for smokers
carrying these genotypes in the presence of a family history
of malignancy. Our ﬁndings point to the presence of a high-
risk group for adenocarcinoma of the pancreas. This cohort
needs further characterisation and replication in larger
population based and molecular epidemiological studies.
Identifying risk might help stratify individuals for pan-
creatic cancer screening but screening is not well established,
the pickup rate is low and the false positive rate is relatively
high. Surgery usually means a total pancreatectomy with
all its potential complications. If we are able, however, to
better quantify the risk, the beneﬁts might be greater and
identifying genetic and environmental factors is important.
With the completion of the human genome project and
advances in molecular epidemiological techniques, these
low penetrant/polymorphic genes should become more
frequently identiﬁed and their function understood; for
example, genome-wide association studies have identiﬁed
smokers with a non-O blood group as a signiﬁcant high
risk group for pancreas cancer as compared to nonsmokers
of non-O blood group (OR 2.68 (95% CI: 2.03–3.54))
[43, 44]. Similarly identiﬁcation of high-risk groups such as
smokers with a positive family history of cancer could have
implications for the earlier diagnosis by making screening
for the disease possible leading to the prospect of long-term
survival if not cure for more patients.
5.Summary
Smoking increases the risk for pancreatic cancer by about
3 times and current smokers develop the disease about 6-7
years earlier than nonsmokers.T h i sr i s ki si r r e s p e c t i v eo fa
family history of any malignancy. In the presence of a family
history of any malignancy, regardless of smoking, the risk for
pancreatic canceris double.Inindividuals with a ﬁrst-degree
family history of malignancy, the development of pancreatic
cancerappearstooccuratalowerlevelofcumulativetobacco
exposurethaninthosepatientswithoutsuchafamily history.
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Explanationof Termsand Abbreviations
FDR: First-degree relatives
caFDR: First-degree relatives of cases
caFDR+: First degree relatives of cases with
a history of malignancy
caFDR−: First degree relatives of cases
without a history of malignancy
coFDR: First degree relatives of controls
coFDR+: First degree relatives of controls
with a history of malignancy
coFDR−: First degree relatives of controls
without a history of malignancy
FDR1: Index cases with a single FDR
with malignancy
FDR > 1: Index cases with more than
1F D Rw i t hm a l i g n a n c y
MONICA
questionnaire:
Monitoring of Cardio-vascular
risks questionnaire
CI: Conﬁdence interval
SNP: Single nucleotide polymorphism
CA19-9: Carbohydrate antigen 19-9
EUS: Endoscopic ultrasound
FNA: Fine needle aspiration
ERCP: Endoscopic retrograde
cholangio-pancreatography
Pack-years of
cumulative smoking:
= (number of cigarettes smoked
per day × number of years
smoked)/20(1 pack has 20
cigarettes).
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